Editas Medicine(EDIT)

Search documents
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Globenewswire· 2024-04-22 20:31
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicines. Editas ...
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
2024-03-13 23:58
Editas Medicine, Inc. (NASDAQ:EDIT) Barclays 26th Annual Global Healthcare Conference March 13, 2024 2:05 PM ET Company Participants Gilmore O'Neil - Chief Executive Officer Erick Lucera - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Gena Wang Good afternoon, everyone, and welcome to Barclays Global Healthcare Conference. My name is Gena Wang. I cover the US mid-cap biotech. It is my great pleasure to introduce our next presenting company, Editas Medicine. With us today we have ...
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
2024-03-12 19:56
Editas Medicine, Inc. (NASDAQ:EDIT) Leerink Partners Global Biopharma Conference March 12, 2024 10:40 AM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - Conference Call Participants Mani Foroohar - Leerink Mani Foroohar Good morning, everyone. Welcome back to the 2024 Global Biopharma Conference, Inaugural Miami Conference. So welcome everybody down. I am Mani Foroohar, Senior Analyst Genetic Medicines. And I'm very fortunate to be hosting the team from Editas Medicine. How are you doing? Gilm ...
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The Motley Fool· 2024-03-07 08:31
With Citigroup analyst Samantha Semenkow calling on Feb. 29 for shares of Editas Medicine (EDIT -0.66%) to rise from their current price near $10 to reach $16 -- an increase of 45% over her prior estimate -- there's a clear consensus about the stock forming on Wall Street. Based on Semenkow's price target, which is effectively the same as the consensus average price target across analysts following the stock, Editas Medicine is looking at a 70% bump.It could happen. Here's why.This company just got a huge b ...
Editas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)
2024-03-06 22:05
Editas Medicine, Inc. (NASDAQ:EDIT) TD Cowen 44th Annual Healthcare Conference March 4, 2024 12:50 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good afternoon and welcome once again to TD Cowen’s 44th Annual Healthcare Conference. I'm Phil Nadeau, one of Cowen’s biotech analysts, and it's my pleasure to moderate a fireside chat with Editas. We have with us today, Gilmore O'Neill, CEO and Erick Lucera, CFO. Hand it over ...
1 Beaten-Down Stock With 55% Upside, According to Wall Street
The Motley Fool· 2024-03-04 15:30
Although equities have performed pretty well in the past three years, many somewhat speculative and unprofitable stocks have struggled as investors have turned their attention away from such corporations. That's the case with Editas Medicine (EDIT -2.47%), a clinical-stage gene editing-focused biotech company.However, many analysts on Wall Street have high hopes for the stock. Editas Medicine's average price target of $15.64 implies an upside of about 55% over its stock price of $10.06 (as of writing). Can ...
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
The Motley Fool· 2024-03-03 02:49
Shares of Editas Medicine (EDIT 4.67%) charged sharply higher this week, soaring as much as 41.6%, according to data from S&P Global Market Intelligence. By the time the market closed on Friday, the stock was still up 34.8%.The catalyst that vaulted the gene editing specialist higher was the company's quarterly report, which included a surprise announcement.Alignment with the FDAOn Wednesday, Editas Medicine released its fourth-quarter results, which were better than investors had hoped. The company generat ...
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
Zacks Investment Research· 2024-02-29 14:46
Editas Medicine, Inc. (EDIT) incurred a loss of 23 cents per share in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 52 cents. The company had reported a loss of 88 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $60 million in the reported quarter, up significantly from $6.5 million reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate o ...
Editas Medicine(EDIT) - 2023 Q4 - Earnings Call Transcript
2024-02-28 16:11
Financial Data and Key Metrics Changes - The company reported cash, cash equivalents, and marketable securities of $427 million as of December 31, 2023, down from $446 million as of September 30, 2023 [46] - Revenue for the fourth quarter of 2023 was $60 million, primarily from a license agreement with Vertex [47] - R&D expenses increased by $18 million to $70 million compared to the fourth quarter of 2022, reflecting additional sub-license expenses [65] - G&A expenses for the fourth quarter of 2023 were $14 million, down from $18 million in the same quarter of 2022 [78] Business Line Data and Key Metrics Changes - The company has enrolled 40 sickle cell and 9 beta thalassemia patients in the RUBY and EdiTHAL studies, with 18 RUBY patients and 7 EdiTHAL patients dosed [27][41] - The RUBY trial is now considered a Phase 1, 2, 3 study for BLA submission, with alignment on study design and endpoints with the FDA [42][36] Market Data and Key Metrics Changes - The company is focused on the gene editing market, particularly in hemoglobinopathies, and has engaged with the FDA regarding the RUBY trial [34][55] - The competitive landscape includes a recently approved gene editing treatment for sickle cell disease, which the company is monitoring closely [104] Company Strategy and Development Direction - The company aims to drive reni-cel towards BLA and commercialization, strengthen its discovery organization, and increase business development activities [34] - The company has decided not to pursue internal development of a milder conditioning regimen, focusing instead on in vivo HSE medicines [55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for reni-cel to provide a competitive edge in the market [62] - The company plans to provide clinical updates from the RUBY and EdiTHAL trials in mid-2024 and by year-end 2024 [39] Other Important Information - The company has strengthened its senior leadership team with experienced professionals in drug development and commercialization [34] - The company has activated over 20 sites for the RUBY trial, with ongoing patient recruitment and dosing [100] Q&A Session Summary Question: Can you elaborate on the hemolysis markers being tracked? - The company tracks multiple hemolysis markers including reticulocyte, LDH, and bilirubin, and uses various instruments to measure patient-reported outcomes related to quality of life [70] Question: Can you share insights into your FDA conversations regarding the RUBY trial? - The company has aligned with the FDA on the RUBY trial as a Phase 1, 2, 3 study, including endpoint, sample size, and study design [72][74] Question: How does the Phase 1, 2, 3 designation impact the BLA path? - The designation allows for a seamless transition to support the BLA, utilizing all patient data from the study [102][88] Question: What are the latest thoughts on how reni-cel fits in the market? - The company sees robust market development and initial interest from stakeholders, with ongoing engagement in clinical studies [105] Question: Can you provide an update on the CRISPR-Cas9 appeal case? - The Court of Appeals has yet to schedule an oral hearing, but it is expected to occur sometime in 2024 [96] Question: What is the status of the adolescent cohort in the RUBY study? - The adolescent cohort has been initiated, with high interest and demand from patients [59] Question: How is the company addressing the patient experience with reni-cel? - The company is pleased with the number of apheresis cycles required and reports that all patients have achieved engraftment within 30 days [167]
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research· 2024-02-28 14:11
Editas Medicine (EDIT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 55.77%. A quarter ago, it was expected that this genome editing company would post a loss of $0.64 per share when it actually produced a loss of $0.55, delivering a surprise of 14.06%.Over the last four quarters, the compa ...